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Summary. Investigation of covalent DNA binding in 
vivo provided evidence for whether a test substance 
can be activated to metabolites able to reach and react 
with DNA in an intact organism. Fora comparison of 
DNA binding potencies of various compounds tested 
under different conditions, a normalization of the 
DNA lesion with respect to the dose is useful. A cova-
lent binding index, CBI = (JliDol chemical bound per 
mol DNA nucleotide )/(mmol chemical administered 
per kg body weight) can be determined for each com-
pound. Whether covalent DNA binding results in tu-
mor formation is dependent upon additional factors 
specific to the cell type. Thus far, all compounds which 
bind covalently to liver DNA in vivo have also proven 
tobe carcinogenic in a long-term study, although the 
liver was not necessarily the target organ for tumor 
growth. With appropriate techniques, DNA binding 
can be determined in a dose range which may be many 
orders of magnitude below the dose Ievels required for 
significant tumor induction in a long-term bioassay. 
Rat liver DNA bindingwas proportional to the dose 
of aflatoxin B1 afteroral administration of a dose be-
tween 100 J.Lgfkg and 1 ngfkg. The lowest dose was in 
the range of generat human daily exposures. Demon-
stration ofa Iack ofliver DNA binding (CBI<0.1) in 
vivo for a carcinogenic, nonmutagenic compound is a 
strong indication for an indirect mechanism of carci-
nogenic action. Carcinogens of this class do not di-
rectly produce a change in gene structure or function 
but disturb a critical biochemical control mechanism, 
such as protection from oxygen radicals, control of 
cell division, etc. Ultimately, genetic changes are pro-
duced indirectly or accumulate from endogenaus 
genotoxic agents. The question of why compounds 
which act via indirect mechanisms are more likely to 
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exhibitanonlinear rangein the dose-response curve as 
opposed to the directly genotoxic agents or processes is 
discussed. 
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Introduction 
Covalent DNA binding is a common activity of a 
great nurober of potent organic chemical carcinogens. 
The compounds are either chemically reactive per se 
( = activation independent genotoxin) or require met-
abolic processes to form chemically reactive interme-
diates ( = activation dependent genotoxin). DNA 
binding and its biological consequences (e.g., muta-
tions) can be studied in a nurober of test systems. An 
in vivo assay with Iabaratory animals offers the prime 
advantage of intact mammalian metabolism without 
the distortion often encountered with in vitro short-
term tests, where for instance alkyl hydrazines, pyrrol-
izidine alkaloids, safrole, or dimethylnitrosamine do 
not produce a mutagenic response which would reflect 
their carcinogenic potency. An investigation of cova-
lent DNA binding in vivo can therefore provide qual-
itative and quantitative evidence for whether a test 
substance can be activated to metabolites able to reach 
and react with DNA in an intact organism. Fora com-
parison of various compounds tested under different 
con9itions a normalization of the DNA lesion to the 
dose is useful. For this purpose, Lutz and Schlatter 
(1977) proposed the use of a covalent binding index, 
CBI = (J.Lmol chemical bound per mol DNA nucleo-
tide)/(mmol chemical administered per kg body 
weight). Methods currently used in DNA binding ex-
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periments will be reviewed critically, and a number of 
toxicological applications for the use of CBis will be 
discussed. 
Materials and methods 
Three methods are mainly used for the in vivo determination of the 
DNA binding activity of a chemical. 
Radiolabeled test compound. This method involves the administra-
tion of radiolabeled test substance to a laboratory animal. After an 
appropriate time interval to allow for absorption, distribution, me-
tabolism (hours), and possibly DNA repair (days to weeks), DNA is 
isolated from the liverandadditional organs ofinterest. DNA must 
be extensively purified until the specific activity remains unchanged. 
This ensures that noncovalently bound chemical has been completely 
removed. DNA is also isolated from an untreated animal to measure 
the background radioactivity values. This control is essential to 
prove that Iabaratory organisation and technique were adequate to 
isolate DNA without incurring radioactive contamination. lt must 
be remernbered that mCi amounts of radiolabet are administered to 
the animals (1 mCi=2.22 x 109 dpm) and that a few dpm on the 
DNA could be measurable and attributable to the treatment. In the 
author's laboratory, specific apparatus and working areas are re-
served exclusively for the fmal steps of DNA isolation, such as pre-
cipitation and constituent analysis. In this way, contamination from 
radioactive glassware etc. can be kept to a minimum. Controls for 
noncovalent associations of test compound or metabolites with 
DNA have also been described (Caviezelet al.1984). The specificac-
tivity of chromatin protein is also determined in order to estimate 
whether an unavoidable protein contamination of the DNA might 
be responsible for the measured DNA radioactivity (Caviezel et al. 
1984). 
The radiotabei should be introduced into the molecule in such 
a position that putative reactive metabolites may still be expected to 
carry the Iabel (Lutz 1984). In some cases, the test compound is de-
graded to release tritiated water or small radiolabeled fragments. 
Since these molecules could be used in the de novo synthesis of nu-
cleic acids, radiolabet might also be found in the natural nucleotides. 
This source of DNA radioactivity is not related to covalent DNA 
binding and must be detennined separately. Forthis purpose, DNA 
is degraded, the natural nucleotides are separated from the nucleo-
tide-carcinogen adducts, and the specific activity ofthe natural DNA 
constituents is determined. Only the radioactivity eluting without de-
tectable optical density (too few molecules) can represent DNA bind-
ing (Sagelsdorff et al. 1983). 
The method described here is dependent on the availability of 
radiolabeled test compound. lt is therefore most appropriate for the 
investigation of compounds which have to be radiosynthesized for 
other purposes, such as kinetics and metabolism studies. 
Antibody techniques. The production of antibody against DNA ad-
ducts depends upon the prior synthesis of the specific adduct as an 
antigenic determinant (Müller and Rajewsky 1981). This method is 
therefore not used to detennine whether or not a compound can 
undergo DNA binding but rather to answer specific questions about 
a compound whose genotoxicity is already known. Production and 
selection of good antiborlies can represent a major challenge. The 
whole expenditure therefore is justified only if detailed study of the 
role of a specific adduct in the process of chemical carcinogenesis is 
intended. Once good antibody material is available, then the method 
can be very sensitive, requiring only microgram amounts ofDNA for 
analysis. 
32 P-Postlabeling technique. With this method, 32P-labeled phosphate 
from 32P-ATP is attached enzymatically to the 5' position ofnucleo-
tide-3'-monophosphates after enzymic degradation of DNA (Ran-
derath et al. 1985; Gupta 1985). Afterseparation ofthe natural nu-
cleotide-bis-phosphates from the adduct nucleotide-bis-phosphates 
by chromatography, the amount of adduct can be quantified by 
counting the 32P. Because of the high specific 32P-activity available 
(e.g. 5,000 Cijmmol), as little as 10- 17 mol ( = 6 x 106 molecules) 
phosphorylated adduct would be detectable with 100 dpm 32P. As-
suming 1 adduct per 10 7 nucleotides, only 6 x 1013 nucleotides would 
be required for analysis, i.e., the DNA from about 3,000 rat liver 
cells. The original method using PEI cellulose sheet chromatography 
is currently being replaced by HPLC methods in a nurober of labo-
ratories. This has been donein order to separate the adduct nucleo-
tides from the natural nucleotides before the phosphorylation step so 
that the amount of radiolabeled A TP necessary can be reduced to the 
actual amount of adduct to be phosphorylated. lt also re:riuuns to be 
shown to what extent various adducts interfere with the phosphory-
lation step. So far, a quantitative analysis of the level of adduct for-
mation is dependent on the knowledge of the relative yield of phos-
phorylation from natural and adduct nucleotides. 
This DNA binding assay does not require radiolabeled test com-
pound, it can be used to study chronic treatments and complex mix-
tures, and it could also detect endogenous DNA lesions. 
Results and discussion 
Carcinogenic potency of mutagens 
The CBis can be calculated from experiments using 
more than 100 chemicals. Most data are available for 
Iiver DNA at the time of maximum DNA darnage 
after single administration. Figure 1 shows the quanti-
tative correlation of carcinogenic potency vs CBI for 
Ii ver DNA. The TD50 values were taken from Gold et 
al. (1984) and were converted to molar units. CBI 
values for liver DNA were from the review by Lutz 
(1979) and from more recent original publications (see 
legend to Fig. 1 ). Only metabolic activation-depen-
dent carcinogens which were also positive in in vitro 
tests for mutagenicity were included. The DNA 
binding and carcinogenicity study had to be per-
formed in the same animal species. No other selection 
wasmade. 
The correlation coefficient (r = 0.81) was surpris-
ingly high, considering that the DNA binding data 
have been determined in liver, although the liver was 
not necessarily the target organ for the induction of 
tumors. It seems that the determination ofliver DNA 
binding of mutagenic compounds could be used as a 
semiquantitative short-term test for carcinogenic po-
tency to predict that mutagens exhibiting a CBI ofbe-
low 10 are most probably weak carcinogens, that a 
CBI in the order of 100 stands for moderately strong 
carcinogens, and above 1,000 for potent carcinogens. 
However, the target organ cannot be predicted on the 
basis ofDNA binding data alone. 
Two experimental shortcomings are probably re-
sponsible for most of the deviations from the re-
gression line in the above correlation of carcinogenic 
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Fig. 1. Cerrelation of carcinogenic potency with covalent binding to liver DNA for 29 mutagens for which data have been published for 
the same animal species. Carcinogenic potencies from Gold et al. (1984), after conversion to molar units. CBI values from Lutz (1979) unless 
stated otherwise in the list of abbreviations arranged below in increasing carcinogenic potency. Bz, benzene; CCI4 , carbon tetrachloride (Levy 
and Brabec 1984); Ani, aniline (McCarthy et al. 1985); AcrN, acrylonitrile (Farooqui and Ahmed 1983); VC, vinyl chloride (Bergman 1982); 
Safr, safrole (Randerath et al. 1984); TCE, 1,1,2-trichloroethane (Mazzullo et al. 1985); tBPP, tris(2,3-dibromopropyl)phosphate (Morales 
and Matthews 1980); Ure, urethane; CMAni, 4-chloro-2-methylaniline (unpublished); NMAni, nitrosomethylaniline; DCE, 1 ,2-dichloroethane 
(Prodi et al. 1985); DNT, 2,4-dinitrotoluene (Kedderis et al. 1984); NPyrr, nitrosopyrrolidine (Hunt and Shank 1982); BP, benzo[a]pyrene 
(Shertzer 1983); DMAAB, N,N-dimethyl-4-aminoazobenzene FANFT, N-[5-nitro-2-furyl)-2-thiazolyl]formamide (Morton 1982); CPh, 
cyclophosphamide; Bzd, benzidine (Martin and Ekers 1980); DBE, 1,2-dibromoethane; AAF, 2-acetylaminofluorene; Aza, azaserine (Zurlo et 
al. 1982); NDMA, nitrosodimethylamine; Strtoz, streptozotocin (Bennett and Pegg 1981); DMH, 1,2-dimethylhydrazine; Steri, sterigmato-
cystine (Reddy et al. 1985); Pcz, procarbazine (Wiestler et al. 1984); NDEA, nitrosodiethylamine; AFB1, aflotoxin B1 
potency with DNA binding ability. Firstly, most sturl-
ies have concentrated on the Ievel of DNA binding at 
the time ofmaximum DNA darnage after a single ad-
ministration. It would be more appropriate to rnea-
sure the DNA darnage after chronic exposure so that 
a steady state Ievel could be assessed which would take 
into account the cornpeting processes ofDNA binding 
and DNA repair. Secondly, most DNA binding agents 
produce more than one single adduct. Each adduct has 
its specific biological consequences and repairability. 
An overall determination ofthe DNA darnage cannot 
possibly precisely reflect the carcinogenic potency. 
This is weil illustrated with nitrosodimethylamine 
(NDMA) vs nitrosodiethylamine (NDEA). The latter 
gives rise to only one-tenth the Ievel of DNA adducts, 
yet is ten times more carcinogenic than NDMA. This 
could be due to the fact that ethylations and methyl-
ations are distributed and repaired differently on the 
DNA and that the NDEA-DNA lesion can result in 
rnore critical gene alterations. Alkylation of DNA with 
small groups has been shown to occur on more than a 
dozen different positions in the DNA (Hemminki et al. 
1986). In such a situation, the determination of total 
DNA binding can Iead to an overestimation of the 
danger if only a minor fraction of the adducts is po-
tentially harmful. Large adducts, however, are in most 
cases formed in only one or two, sometimes three dif-
ferent positions. With such bulky adducts, it has never 
been shown that binding to a specific position remains 
without biological consequence. Here, the determina-
tion of total binding might give a truer prediction of 
the potential hann. 
The fact that some carcinogens do bind to liver 
DNA without causing liver tumors is an indication 
that DNA bindingisnot sufficient for carcinogenesis. 
Besides the requirement for cell division (Lutz et al. 
1984) other conditions might have to be met. Whether 
covalent binding results in tumor formation is there-
fore dependent upon additional, cell type-specific pro-
cesses. 
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Gareinagens which do not bind to DNA in vivo 
In the course of our investigations of putative DNA 
binding ability of carcinogenic compounds which are 
not mutagenic in vitro we have found a number of 
compounds which do not fit into the correlation 
shown in Fig.t (plasticizers DEHP and DEHA, von 
Däniken et al. 1984; hypolipidemic agents clofibrate 
and fenofibrate, von Däniken et al. 1981; TCDD, Po-
land and Glover 1979). They do not bind covalently to 
DNA (CBI <0.1 in most cases) but are definitely car-
cinogenic in a long-term bioassay. In Fig. 1, these 
compounds would have to be placed at the bottom 
right. Demonstration of a Iack of liver DNA binding 
in vivo is therefore a strong indication for a mecha-
nism of tumorigenic action not directly related to a 
covalent interaction with DNA. This mechanistic as-
signment can clearly be made with strong carcinogens 
(e.g., TCDD), because alimit of detection ofCBI <0.1 
places a strong carcinogen four to five orders of mag-
nitude outside the correlation. With weak carcinogens 
like DEHP, the distinction is more difficult because 
the possibility that a DNA binding activity with as 
little as CBI = 0.1 might be responsible for a few tu-
mors induced at high dose Ievels cannot be excluded. 
Oncogene activation 
It is our understanding that a cancer cell genome dif-
fers from its normal counterpart by a nurober of 
changes in gene structure or regulation. It has emerged 
recently that oncogenes can be activated by gene mu-
tations or by structural or numerical chromosomal 
mutations. This type of change could be induced di-
rectly with genotoxic agents. Alteration of structure 
Inhalation Exposure 
0 2 3 4 
and function of critical protein molecules, for instance 
by protein alkylation, could also result in a loss of 
growth control in a cell which could then become re-
fractory to regulation of cell division. The probability 
for this to result in heritable changes seems to be much 
lower, however, than DNA-mediated events. 
Classification of carcinogens according 
to putative shape of dose-response curve 
The study ofbiological mechanisms in chemical carci-
nogenesis also has toxicological importance. It must 
be remernbered that tumor data are only available in 
a dose range which induces between 10% (in some 
specialsituationsdown to 1 %) and 100% cumulative 
tumor incidence (Fig. 2). The range which must nor-
mally be covered by extrapolation from a tumorigenic 
dose Ievel to a "tolerable" exposure level leading to 
one additional tumor in 1 million exposed humans 
spans at least four orders of magnitude. It is obvious 
that the knowledge of the mechanism of action is 
essential for a biologically sound extrapolation model. 
As opposed to other attempts to categorize chemi-
cal carcinogens with respect to experimental protocols 
(e.g., initiator vs promoter), two classes are formed 
here in an attempt to distinguish between those mech-
anisms of action where direct interaction of test com-
pound and DNA shows a linear dose-response curve 
over a wide dose range and other mechanisms where 
it is thought that biological control and response 
mechanisms lead to sigmoidal dose-response relation-
ships. The first group of carcinogens is listed in 
Table 1 part A. It comprises all compounds which 
bind noncovalently or covalently (per se or as metab-
(log ppm) 
I I I I I I I I I I 
(·100%) 0 ~-- -------------------
i ~::_ ~~-----l-.. / -----~ 
'0 
'ü 
s 
-3 
-
Q) 
g) 
c: 
~ 
-4 
-
1: 
.2 
i;i 
ö 
Q. 
-5 
-
CU 
!: 
N Q) 
.· ? .· 
.· .. 
. . 
.. 
.. 
.. 
• ' • ' tolerable risk 
-
-
-
-6----------------------
1 ' ~ I I I I I I I 1 
Fig.l. Cumulative tumor incidence 
from 10-6 to 1 (10- 4 to 100%) as a 
function of the level of inhalation 
exposure (6 h/day, 5 daysfweek, for 2 
years) to FA or VC. Dotted lines: 
slope 1 for VC according to 
hypothesis of direct mechanism of 
action; steeper slope for FA 
according to combination of 
genotoxic and cytotoxic activities 
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Table 1. Attempt to group chemical carcinogens into two classes 
according to the probability of a linear vs a nonlinear dose-response 
relationship (class A and B, respectively) 
A. Direct acting carcinogens 
Agent 
Intercalating agent 
Chemically reactive agent 
- metabolic activation 
independent 
- metabolic activation 
dependent 
Ionizing radiation 
Metal ions 
Early effect related to 
carcino genesis a, b 
Noncovalent DNA binding 
Covalent DNA and protein binding 
Strand breaks (direct) 
Reduced template fidelity 
B. lndirect acting carcinogens and tumor promoters 
Agent 
Ionizing radiation 
Base analogue 
Enzyme inducerjinhibitor 
(also related to bacterial 
enzym.es in gut flora) 
Hormone, growth factor 
Peroxisome proliferator 
Process 
Protein binding without 
detectable DNA binding 
Membrane damage, solid 
state carcinogenesis 
Overnutrition 
Early effect related to 
carcinogenesis b 
Formation of radicals 
Disturbance of nucleotide 
precursor pool 
Change of balance in activation vs 
inactivation pathways: more 
DNA binding by unavoidable or 
endogenaus procarcinogens 
Stimulation of cell division, survival 
of specific cell populations 
Stimulation of cell division, 
increased 02 · radical formation 
Early effect related to 
carcinogenesis b 
Cytotoxicity, necrosis, Stimulation 
of regenerative cell division 
Lipid peroxidation, increased 02· 
radical formation, stimulation of 
regenerative cell division 
Increased O;· radicalleakage 
a It is possible that nonlinear dose-response relationships can result 
from later steps (e.g., saturation of DNA repair) 
b The later effects are believed to involve changes in oncogene 
structure or function 
olites) with DNA. Other direct attacks on stability or 
expression of the genetic information involve radi-
ation-induced breaks. Although these processes are 
considered to follow first order kinetics in a low dose 
range it was not surprising to fmd a flattening out of 
the dose-response curve at the highest dose levels due 
to a saturation ofthe activating enzyme systems [vinyl 
chloride (VC) Fig. 2; benzene]. 
Carcinogens in the second class do not produce a 
change in gene structure or activity directly but dis-
turb a biochemical process (listed in Table 1 part B) 
after the administration of high doses and/or over 
Ionger periods of time. Some of these processes could 
ultimately produce a structural or functional genetic 
change similar to the more direct effect of the geno-
toxic agents or might provide a survival advantage to 
cells which have already passed the initial stages of 
carcinogenic transformation (tumor promotion). The 
dose-response curve for class B carcinogens can in-
clude a nonlinear part if the critical process is regulated 
under normal conditions by allosteric enzymes charac-
terized by an s-shaped dose-response curve. This 
process of cooperativity is often seen in hormonally 
controlled reactions. Carcinogenesis by hormones 
therefore is likely to operate effectively only above a 
critical concentration. 
Oxygen radical-induced DNA darnage as a side 
product of peroxisome proliferation or Iipid peroxida-
tion might be another example where it could be imag-
ined that DNA darnage can be kept minimal thanks to 
endogenaus protective systems like superoxide dismu-
tase, catalase, and peroxidases, but where the high 
dose treatment used in a long-term bioassay over-
whelmes the proteelive processes in such a way that a 
nonlinear increase in DNA darnage results. 
Some chemical carcinogens could act by more than 
one single mechanism and the dose-response would be 
a superposition of the individual curves. Formalde-
hyde (FA) should be mentioned in this respect because 
a minor genotoxicity seems to be expressed only at 
higher dose levels where increased cytotoxicity and re-
generative cell division are found. The resulting steep 
slope seen in the long-term bioassay data could there-
fore be extrapolated to lower dose Ievels until the indi-
rect effects are no Ionger active ( dotted line in Fig. 2). 
Although FA has to be regarded as a morepotent car-
cinogen than VC at the 10% incidence line, itmight be 
less dangeraus at exposures of0.1 ppm because ofthe 
different shapes of the dose-response curves in that 
range of extrapolation. 
It is worth noting that in the very low dose range, 
a linearity between dose and effect could also hold for 
the indirectly acting carcinogens if it is accepted that 
carcinogenicity is an unavoidable ongoing process and 
that exposure to a xenobiotic carcinogen merely accel-
erates this process by an increment strictly propor-
tional to the dose (see Crump et al. 1976 for the nec-
essary mathematics). The level of background carci-
nogenesis might be genetically controlled so that the 
risk from exposure to a chemical carcinogen might 
vary in different population groups. This situation 
might for instance be met in the constitutive leakage 
of oxygen radicals from cytochrome oxidase during 
the reduction of molecular oxygen (e.g., basal metab-
olism, overnutrition). One should not, therefore, al-
ways expect true thresholds. Still, a sigmoidal rangein 
the dose-response curve can have a marked effect in a 
risk assessment. 
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The tenn tumor promoter has rarely, been men-
tioned so far although most discussions of carcinogenic 
mechanisms of action center araund initiators and 
promotors. These terms emerge from specific ex-
perimental procedures using two different consecutive 
treatments to induce tumors. This procedure does not 
allow so far to distinguish between subclasses within 
class B. 
Dose-response for D NA binding in vivo 
With appropriate techniques, DNA binding can be de-
termined in a dose range which can be orders of mag-
nitude below the dose Ievels required for a significant 
increase in tumor growth in a long-term bioassay. The 
above hypothesis of a linear dose-response curve in 
the low dose range for genotoxic agents can therefore 
be tested with DNA binding. Aflatoxin B1 (AFB1) is 
available in the tritiated form with specific activities of 
the order of 10 Ci/mmol. Thanks to its extremely high 
CBI of 104, dose Jevels as low as 1 ng/kg rat Iead to de-
tectable radioactivity in liver DNA. The general hu-
man population is exposed to AFB1 in this dose range. 
In certain areas of the world, the exposure can be 100 
times this level. Carcinogenicity data are available 
from exposure in the J.lg/kg range. It would therefore 
be interesting to see whether DNA binding decreases 
linearly with dose ifthe gap between carcinogenic and 
environmental exposure is investigated. Nonlinearity 
could for instance result if the activation of AFB 1 to 
DNA binding metabolites or the inactivation to non-
toxic compounds were not governed by first order 
processes. Nonlinearity would also result if the DNA 
repair enzymes could cope with the low DNA darnage 
caused by 1 or 10 ng/kg, but not the darnage caused by 
10 J.Lg/kg. Figure 3 shows the covalent binding of 
AFB 1 to rat liver DNA, 24 h afteroral administration 
of a single dose ranging from 1 ngfkg to 100 !lgfkg. A 
linear correlation of DNA binding with dose was 
found with slope of 1 in a double-logarithmic plot. lt 
must be concluded that the processes which control 
the Ievel of DNA darnage during 24 h after adminis-
tration all follow first order kinetics. It is therefore 
highly probable that a linearextrapolationalso holds 
for the tumor incidence, unless chronic treatment with 
AFB 1 introduces nonlinearity at some point. 
It might beillustrative here to visualize the number 
of AFB1-DNA adducts produced by 1 ng/kg. The 
mean liver DNA bindingwas 2 x 10-2 pgfmg DNA. 
Converting this value to molar units with the molecu-
lar weights of 312 and 309 for AFB 1 and an average 
DNA nucleotide (Nt), respectively, it can be calcu-
lated that there were about 2 adducts per 1011 Nt de-
termined. At higher dose Ievels which would, upon 
daily administration, Iead to a detectable increase in 
0 
AFB 1 Dose [ng/kg] 
Fig.3. Liver DNA binding of AFB1, 24 h aftersingleoral adminis-
tration of 3H-AFB 1 to male F344 rats, as a function ofdose 
liver tumors (1 J.Lgfkg), the corresponding DNA darn-
age would be of the order of 3 adducts per 108 Nt. The 
steady state Ievel upon chronic administration was 
found in additional experimentstobe about 20 times 
higher, i.e., 6 adducts per 107 Nt. Given that a liver 
cell of a young adult rat contains about 2 x 1010 Nt, 
this means that AFB 1 -induced carcinogenesis in rat 
liver might become overt at a steady state DNA darn-
age of 104 AFB1 adducts per cell. It will be interesting 
to determine the Ievel ofDNA adducts required for tu-
mor formation for other genotoxic agents and for 
other target cells. This might give valuable informa-
tion on the biological effect of different adducts and 
on the additional requirements in each cell type for 
carcinogenic transformation. 
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